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Abstract
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infection caused by a novel Bunyavirus. Analysis on
the dynamic changes of clinical, laboratory, and immunological abnormalities associated with SFTS in a concurrent study is
lacking. Thirty-three SFTS patients were admitted to Jiangsu People’s Hospital, Nanjing, China, and diagnosis was made
based on the clinical symptoms and positive viral RNA detected by RT-PCR. Four patients deceased and twenty-nine
survived. Blood samples were collected every other day between Day 5 and Day 15 from the onset of fever. Samples from
healthy volunteers were used as normal controls. Peak viral RNA load, serum enzymes, IL-6, and IL-10 were significantly
higher in deceased patients compared to survivors. Viral load, serum enzymes, and cytokines declined in survivors within 2
weeks from onset of fever. CD69+ T cells were elevated early after infection while HLA-DR+ and CTLA4+ T cells were
elevated during the recovery phase of those who survived. High level SFTSV viral load was concurrently observed with
reduced PLT, elevated serum enzymes, elevated pro-inflammatory and anti-inflammatory cytokines, and activation of CD69+
T cells. The degree and pattern of changes in these parameters may indicate the clinical outcome in SFTSV-infected patients.
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Introduction
Severe fever with thrombocytopenia syndrome (SFTS) is an
emerging infectious disease recently discovered in China [1–5].
The causative agent of this illness, severe fever with thrombocy-
topenia syndrome virus (SFTSV), was identified as a novel tick-
borne Bunynavirus in genus Phlebovirus; it is also named
Huaiyangshan virus, since the original cases were identified in
the Huaiyangshan Mountains in 2009 [1,6,7]. It was reported that
SFTSV can be transmitted in several ways: 1) patients can be
infected through a tick bite; the virus has been detected in
Haemaphysalis longicornis ticks [1,7] and/or 2) through person-
to-person transmission via contact with blood from patients with
SFTS [8]. Sporadic and clustered SFTS endemics have been
documented in at least six provinces in Northeastern, Eastern, and
Central China since 2009 [1,3,9].
The typical clinical presentation of SFTS is acute fever and
thrombocytopenia (platelet count less than 100,000/ml), in
addition to other non-specific features including muscle pain,
severe malaise, nausea, vomiting, and diarrhea [1,3,6–8]. A high
mortality rate (ranging from 12%–30%) has been reported for
SFTSV-infected patients [1,6,9]. The exact mechanism of SFTSV
pathogenesis remains unclear but it is generally suspected that
immunopathology plays a key role [10,11]. As with other viral
infections, immune activation and exaggerated cytokine produc-
tion in the form of cytokine storm can potentially drive the SFTS
disease process. Several studies reported that SFTSV infection
could lead to elevated levels of serum cytokines, which might
contribute to disease severity and clinical outcome [6,12,13]. In
separate reports it was shown that the viral infection induced
CD3+CD8+ and CD3+CD4+ T cell population changes [11,14].
However, almost all of the previous reports showed data collected
at one or two time points of the disease process rather than
determining dynamic changes in key lab test results and
immunological markers incurred during the critical clinical period
shortly after infection.
In the current report, changes in SFTSV viral load, platelets
and white blood cell counts, levels of key serum enzymes, cytokine
profile and changes in two important T subset populations, were
measured every other day during the first 10–15 days of
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hospitalization for four deceased patients and twenty-nine
survivors diagnosed with SFTSV infection. Information learned
from the current study provide a better understanding on the
relationship between clinical disease progression and key clinical
lab and immunological parameters. Such information is also useful




Between May 2011 and July 2013, thirty-three patients (16
males and 17 females) (Table 1), with confirmed SFTSV infection
based on diagnostic guidelines from the Chinese Ministry of
Health [15], were admitted to the Department of Infectious
Diseases, First Affiliated Hospital of Nanjing Medical University,
Nanjing, China. These patients were from the rural areas of three
Eastern China provinces (17 patients from Anhui, 16 patients from
Jiangsu, and 1 from Shandong). There was no geographical
connection between the four patients who died (2 from Anhui and
2 from Jiangsu). In addition to the SFTSV-infected patients, thirty-
two healthy volunteers (21 males and 11 females) were also
enrolled in this study (Table 1) to serve as normal controls. Written
informed consent was obtained from all participants and the study
was approved by the Institutional Review Board at First Affiliated
Hospital of Nanjing Medical University.
Sample collection and processing
All SFTSV-infected patients received standard antiviral and
standard support treatments after admission to the hospital based
on SFTS treatment guidelines from the Chinese Ministry of
Health. Individual identification codes were given to each
participant and blood samples were collected under identification
codes. For SFTSV-infected patients, samples were collected during
hospitalization at Days 5, 7, 9, 11, 13, and 15 after onset of fever
while blood samples from healthy donors were collected at a single
time point at the time of enrollment.
Lab tests and assays
Blood cell and platelet counts were measured by Japanese
SYSMEX XE2100 fully-automatic blood cell analyzer. Japanese
Olympus AU5400 fully-automatic biochemical detector was used
to determine levels of alanine transaminase (ALT), aspartate
transaminase (AST), lactic dehydrogenase (LDH), and creatine
kinase (CK).
The TaqMan real-time fluorescent quantitative PCR method
was used to detect SFTSV viral load. The virus RNA was
extracted from the plasma samples using a RNA extraction kit and
RT-PCR amplification was conducted immediately on the
fluorescent quantitative PCR detector (ABI StepOne Plus).
SFTSV RNA was detected with the specific primers targeting
the highly conserved region of SFTSV L, M, and S genes [1,16].
The RT-PCR reaction system was in a volume of 25 ml; reaction
conditions were 50uC for 15 min with 1 cycle; 95uC for 15 min
with 1 cycle; 94uC for 15 sec, 55uC for 45 sec, and 55uC with 45
cycles. Fluorescent signals were collected by FAM channel.
Lymphocyte subpopulations and T cell activation profiles in
patients’ PBMC were analyzed by flow cytometry with florescent-
conjugated T cell surface markers: florescent-conjugated mouse
anti-human CD3-PerCP Cy5.5, CTLA-4-PE, CD4-FITC, CD28-
PE, CD8-PE, CD69-FITC, CD25-PE, CD56-PE, HLA-DR-
FITC, and isotype controls: mouse IgG1-PE and mouse IgG1-
FITC (BD Bioscience, CA, USA). Cell populations were analyzed
with FACS Calibur Flow Cytometer and CellQuest software (BD
BioScience).
Serum cytokines were detected using Human Th1/Th2/Th17
Cytometric Bead Array (CBA) Kit (BD BioScience) according to
the manufacturer’s instructions. The flow cytometer (FACS
Caliber) was used to detect IL-2, IL-4, IL-6, IL-10, TNF –a,
IFN-c, and IL-17A levels in the serum. The detection sensitivity of
each cytokine was 2.5 pg/ml.
Statistical analysis
The results were analyzed using statistical software SPSS17.0
for Windows (SPPS, an IBM Company). Mann-Whitney U non-
parametric test, Student’s t-test, or Rank-sum test, where
appropriate, were used to compare the mean value of any two
groups (deceased patients vs. survivors, or infected groups vs.
normal control group), with p,0.05 considered statistically
significant.
Results
During the period from May 2011 and July 2013, 33 patients
with laboratory-confirmed SFTSV infection were admitted to
Jiangsu People’s Hospital, Nanjing, China. These patients share
the similar clinic manifestations of SFTS, including acute fever
(.38uC), weakness, anorexia, nausea and vomiting, as well as
disturbance of consciousness, ecchymosis, and gastrointestinal
hemorrhage for those in critical condition (Table 1), as well as the
hallmark thrombocytopenia (platelet count ,46109/L). At
admission, all patients enrolled in this study had confirmed
positive SFTSV in blood samples determined by reverse-
transcriptase polymerase chain reaction (RT-PCR) with designat-
ed primers for SFTSV L, M, S genes. During hospitalization, all
patients received similar treatment based on guidelines from the
Chinese Ministry of Health [15]. Four died within 1–3 days after
admission (7–9 days after onset of fever) and 29 patients recovered
from the illness. The length between symptom onset to admission
did not contribute to the mortality as those deceased were
admitted on Day 7 of symptom onset while the median time of
admission for those who survived was 6 days (range 3–10 days)
(Table 1). There was no gender bias for the deceased (2 males/2
females) and survivors (14 males/16 females) patients. On the
Table 1. Study cohorts.
Groups No. of Subjects Age range (average) Gender (M/F) Day of admission (range, median)*
Survivors 21 33–78 (58) 11/10 3–10 (5)
Deceased patients 3 58–75 (70) 2/1 7 (7)
Healthy Controls 32 18–60 (42) 21/11 NA
* Days after symptom onset.
doi:10.1371/journal.pone.0091679.t001
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other hand, the median age of the deceased patients (70 years) was
notably older than the median age of survivors (59 years), but not
statistically significant due to a small sample size (Table 1).
While all patients had easily detectable SFTSV in their blood,
SFTSV viral load among survivors peaked shortly after admission
(within 7–11 days of symptom onset) and then dropped rapidly
during the remaining period of the study (Fig. 1A). In contrast,
three out of four deceased patients who were admitted on Day 7 of
disease onset died within three days of admission with much
higher levels of viral load while one of the deceased patients had
similar levels of viral load to those who survived (Fig. 1A). When
the viral loads on Day 9 for both groups were compared, the mean
log viral load for the deceased patients (8.85, range 6.67–9.76) was
about 1000 fold higher than the mean log viral load in the
survivors (5.92, range 2.66–7.94) (p,0.0001) (Fig. 1B).
As indicated by the namesake of this disease, platelet (PLT)
counts in all SFTSV-infected patients were low when the diagnosis
was made, as evidenced by levels half of the normal range (100–
3006109/L). The level of drop in PTL was similar between
deceased patients and survivors (Fig. 2A). After patients were
admitted to hospital, their PLT levels improved steadily, partially
due to treatment. PLT levels returned to a normal range on Day
13 among the survivors while those who died did so before Day 9
of disease onset with low PLT levels.
Parallel to PLT, white blood cell (WBC) counts were also below
the normal range (4.0–9.06109/L) between 5–6 days after onset of
fever but returned to normal around Day 9, earlier than PLT
(Fig. 2B). Interestingly, those who died had WBC counts within
normal range, albeit at the lower end of the normal range. It is
likely that these patients were admitted on Day 7, slightly later
than many of the other patients, and their WBC went up further
after admission.
SFTSV-infected patients had acute tissue damage as indicated
by multiple elevated key serum enzymes (Fig. 2C–F). ALT, AST,
CK, and LDH were all highly elevated in both deceased patients
and survivors; levels in the deceased patients were significantly
higher than those in the survivors (Fig. 2C–F, Table 2). Our
analysis further demonstrated that peak elevations were at the time
of admission, about 5 days after the onset of symptoms. AST, CK,
and LDH levels gradually declined among the survivors while
ALT levels remained elevated for a longer time. All four patients
died before Day 9 from symptom onset while all these biomarkers
were highly elevated.
Because it is suspected that virus-induced immunopathology
may be involved in the tissue damage observed in both clinical
presentation and abnormal lab tests, changes in important T cell
subsets in SFTSV-infected patients were measured. Both CD8+/
CD69+ and CD4+/CD69+ T cells were significantly elevated
early in infection (Fig. 3A and 3B). At Day 9 after disease onset,
mean percentages of CD4+/CD69+ T cells were 3.62% in
survivors and 10.52% in later deceased patients while the normal
control group was 1.12%. CD8+/CD69+ T cells were 3.02% in
survivors and 11.15% in later deceased patients while the normal
control group was 0.51%. Elevations in these T cells in later
deceased patients were significantly higher than the elevation
observed in survivors (p = 0.045 for CD4+/CD69+ T cells and
p= 0.009 for CD8+/CD69+ T cells). These T cells gradually
returned to normal levels in survivors around 2 weeks after disease
onset.
HLA-DR+ T cells were also measured (Fig. 3C and 3D). The
deceased patients had an early elevation of CD8+/HLA-DR+ T
cells while these cells went up later among survivors, reaching peak
levels at Day 13 after disease onset before coming down, although
remaining higher than the normal control group (p,0.001). In
contrast, CD4+/HLA-DR+ CD4 T cells went up at the same time
for both survivors and deceased patients, and the levels continued
to go up through the entire study period for survivors and were
also much higher than observed for the normal control group
(p = 0.039).
CTLA4+ T cells showed a different pattern. Both CD8+/
CTLA4+ and CD4+/CTLA4+T cells went up around Day 11–13
from disease onset (Fig. 3E and 3F) and continued to go higher
than observed in the normal control group during the remaining
study period (p,0.001). For deceased patients, they died around
Day 9 so CTLA4+ T cell levels were not significantly elevated.
CD28+ T cells were also measured but no significant differences
were observed between SFTSV-infected patients and healthy
donors (data not shown).
Specific cytokines were measured further to identify those that
may be involved in the pathogenesis of SFTS. Among the seven
Figure 1. Severe fever with thrombocytopenia syndrome virus (SFTSV) RNA loads in blood. (A) The kinetics of viral RNA levels of
individual patients between 5–15 days after onset of fever during hospitalization. Each curve represents one patient. The red curves indicate the
deceased patients while the black curves represent the survivors. (B) The viral loads of the deceased patients and survivors as indicated on Day 9 after
onset of fever. Each dot represents one patient. Statistical significance (p,0.0001) of viral loads between deceased patients and survivors is indicated.
doi:10.1371/journal.pone.0091679.g001
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cytokines measured in this study, there were no significant
differences for IL-2, IL-4, TNF-a, or IL-17A in serum samples
between SFTSV-infected patients (both deceased and survivors)
and the normal control group (Fig. 4A). However, significant
elevations of serum IL-6, IL-10, and IFN-c were discovered in
deceased patients, not only compared to the normal control group
but also to survivors (Fig. 4B). For survivors, both IL-6 and IL-10
were elevated but significantly only compared to the normal
Figure 2. The kinetics of platelet (PLT) (A) and white blood cell (WBC) (B) counts, serum alanine transaminase (ALT) (C), aspartate
transaminase (AST) (D), lactic dehydrogenase (LDH) (E), and creatine kinase (CK) (F) in SFTSV-infected patients. The red and black
curves represent the deceased patients or the survivors, respectively, as the mean cell counts with standard error (A and B) or mean enzyme units/
liter of blood with standard error (C–F) at each time point during hospitalization from Day 5 to Day 15 after onset of fever. The grey area in each
graph indicates the normal range of related lab tests. Statistical significance (p,0.05) was indicated for each enzyme between deceased patients and
survivors on Day 9 from onset of fever (C–F).
doi:10.1371/journal.pone.0091679.g002
Dynamic Changes of Key Parameters in SFTS Patients
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e91679
control group for IL-10 (Fig. 4B, Table 2). IFN-c was actually
lower in the survivors compared to the normal control group
(Fig. 4B). When the kinetics of these three elevated cytokines were
monitored, IL-6 and IL-10 levels showed an upward trend for the
deceased patients; however, in survivors, levels slowly returned to
normal levels (Fig. 5). IFN-c went down for both deceased patients
and survivors.
Discussion
SFTS, which has a 12–30% mortality rate, is one of the most
severe emerging human infectious diseases in China after severe
acute respiratory syndrome (SARS) and avian influenza in the new
millennium. While previous studies have documented the overall
levels of viral load, changes in key lab results, and certain
immunological biomarkers in SFTS patients at a few select time
points, there is no report on the concurrent measurement of key
abnormal findings over the critical acute phase of SFTS after
infection, and no further analysis to relate these dynamic changes
to the severity and course of the disease.
Although thrombocytopenia is a key abnormal finding in SFTS,
its levels in both deceased patients and survivors were very similar
in our analysis, and thus, may not be directly related to disease
severity and death. In contrast, the level of SFTSV viremia is
correlated to disease severity with significantly higher levels in the
deceased patients than in the survivors when measured on Days 7–
9 after onset of fever. Viral loads gradually dropped among
survivors during the recovery phase. The finding is consistent with
other reports that the SFTSV viral load is related to disease
severity [6].
Table 2. Critical parameters that may be associated the
severity of SFTS.
Parameters Survivors Fatal cases
Mean±SE Mean±SE p value
Clinical Parameters
ALT (Units/L) 135.46642.48 161.496118.75 .0.05
AST (Units/L) 233.46689.97 1028.266688.01 ,0.01
LDH (Units/L) 827.796398.59 2550.186120.02 ,0.001
CK (Units/L) 419.136209.92 3264.166332.01 ,0.001
Serum Cytokines
IL-6 (pg/ml) 2.8566.06 1268.886703.47 ,0.0001
IL-10 (pg/ml) 2.9763.53 48.089611.42 ,0.001
doi:10.1371/journal.pone.0091679.t002
Figure 3. Dynamic changes in T cell subsets in SFTSV-infected patients. The red and black curves represent the deceased patient group and
the survivors, respectively. The values are presented as mean percentages with standard error of each T cell subset at each time point during
hospitalization from Day 5 to Day15 days from onset of fever. The green dashed line in each graph indicates the mean percentage in the normal
control group. Statistical significance (p,0.05) was indicated in graphs A and C for the difference of individual T cell subsets between deceased
patients and survivors on Day 9 from onset of fever, and in graphs B, D, E and F for the difference of individual T cell subsets between survivors and
the normal control group on Day 13 from onset of fever.
doi:10.1371/journal.pone.0091679.g003
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SFTSV infection causes tissue injury and organ damage, which
can lead to elevated serum enzymatic markers and death. In all
SFTSV-infected patients, ALT, AST, LDH, and CK were all
elevated above the normal range especially during the acute phase
of the disease, and their peak levels in deceased patients were
significantly higher than in survivors, which is similar to other
reports [6,14] [10]. On the other hand, our kinetics analysis
discovered that ALT was the last one to come down while AST,
LDH and CK started to decrease among survivors very early after
their admission to the hospital. These lab tests may serve great
value for the clinical prognosis of SFTSV-infected patients.
The human immune system responds powerfully to a major
viral infection such as SFTSV. Previous studies found that total
CD3+ T cells and total CD4+ T cells were decreased in SFTSV-
infected patients, more so during acute phase infection, in severe
cases, and in those who eventually die from the disease [11]. At the
same time, there is no significant change in CD8+ T cells [11,14].
Because the measurement of serum cytokines in SFTSV-infected
patients in previous studies actually showed increased levels
consistent with a cytokine storm as expected in a typical major
viral infection, the above data of total T cells was surprising. In the
current study, change within subpopulations of T cells was
investigated and profound T cell activation was discovered.
Three subsets of T cells (CD69+, HLA-DR+ and CTLA4+)
were found elevated in SFTSV-infected patients but their changes
happened at different phases of progression of the disease. CD69
molecule is a human transmembrane C-Type lectin protein and T
cell early activation marker; CD69+ T cells (both CD8+ and
CD4+) were elevated during the acute phase of SFTSV infection
with significant activation in the deceased patients compared to
Figure 4. Serum cytokine profiles in SFTSV-infected patients on Day 7 after onset of fever. (A) Cytokines (IL-2, IL-4, TNF-a, and IL-17) that
were not significantly different between SFTSV-infected patients and normal control group. (B) Cytokines (IL-6, IL-10, and IFN-c) that were
significantly different between SFTSV-infected patients and normal healthy donors. For each cytokine, * and ** indicate the statistical significance at
p,0.05 and p,0.001, respectively.
doi:10.1371/journal.pone.0091679.g004
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the survivors at time points of the peak viremia. This T cell
subpopulation in survivors gradually decreased to normal levels
and was comparable to healthy donors in 2 weeks.
In contrast, HLA-DR+ (a MHC class II cell surface receptor)
and CTLA4+ (a member of the immunoglobulin superfamily on
the surface of helper T cells) T cells (both CD4+ and CD8+) were
elevated during the recovery phase (after the peak viremia) in the
survivors. These cells were low and only measured during the
acute phase of infection for the deceased patients; however, HLA-
DR+/CD8+ T cells were significantly elevated.
An increase in HLA-DR+ T cells is often in response to antigen
binding and signaling. These cells bind to antigens on the surface
of B cells, stimulating B cell proliferation. CTLA4 is a T-cell co-
stimulatory molecule on antigen-presenting cells and transmits an
inhibitory signal to T cells. HLA-DR and CTLA4 may serve as
upregulation markers in the recovery phase and may have a role in
checking and re-balancing the lymphocytes once the viral infection
is under control. Taken together, our data imply that an increase
inCD69+ T cells may be related to pathogenesis while a late
increase in HLA-DR+ and CTLA4+ T cells may indicate the
induction of protective immune responses.
As reported in SARS [17] and pandemic influenza cases
[18,19], patients infected with SFTSV also mounted an exagger-
ated immune response; furthermore, cytokine storm (hypercyto-
kinemia) was responsible for significant damage to body tissues
and organs, potentially resulting in death. In our study, both pro-
inflammatory cytokines (such as IL-6 and IFN-c) and anti-
inflammatory cytokines (such as IL-10) were elevated in SFTSV-
infected patients and levels were dramatically higher in the
deceased patients, which is similar to reports by other groups
[6,10]. More significantly, IL-6 and IL-10 were persistently
elevated in the deceased patients while levels trended down in
survivors, indicating the possibility of using them as biomarkers to
monitor the progression of the disease. Levels of IL-2, IL-4, TNF-
a, and IL-17A were similar to normal healthy donors; this finding
is somewhat different from previous reports showing that TNF-a
was significantly elevated in SFTS-infected patients, especially
deceased patients [6,10]. It is not clear what may have contributed
to this difference but timing of sample collection and different
assay kits are potential factors influencing the final results of
measurement.
Figure 5. The kinetics of serum IL-6 (A), IL-10 (B), and IFN-c (C) in SFTSV-infected patients during hospitalization between Day 5 and
Day 15 from onset of fever. In all three graphs, the red and black curves represent the deceased patient group and the survivors, respectively. The
values were presented as mean cytokine concentrations with standard errors at each time point. The green dashed line in each graph indicates mean
cytokine concentrations in the normal control group. Statistical significance (p,0.05) was indicated between deceased patients and survivors on Day
9 from onset of fever.
doi:10.1371/journal.pone.0091679.g005
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In conclusion, the current study identified concurrent patterns
of dynamic changes for viral load, PLT, key serum enzymes, major
T cell subsets and unique cytokines in SFTS patients, further
extending our understanding of this high risk, emerging viral
infection, which was discovered only a few years ago. Findings on
the involvement of CD69+ as well as HLA-DR+ and CTLA4+ T
cells in SFTSV infection will lead more targeted research on the
mechanism of pathogenesis in the coming future.
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